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Background: Hepatic resection is currently still the best choice of therapeutic strategies for liver cancer, but the
long-term survival rate after surgery is unsatisfactory. Most patients develop intra- and/or extrahepatic recurrence.
The reasons for this high recurrence rate are not entirely clear. Recent studies have indicated that ischemia-
reperfusion injury to the liver may be a significant factor promoting tumor recurrence and metastasis in animal
models. If this is also true in humans, the effects of the Pringle maneuver, which has been widely used in
hepatectomy for the past century, should be examined. To date, there are no reported data or randomized
controlled studies examining the relationship between use of the Pringle maneuver and local tumor recurrence. We
hypothesize that the long-term prognosis of patients with liver cancer could be worsened by use of the Pringle
maneuver due to an increase in the rate of tumor recurrence in the liver remnant. We designed a multicenter,
prospective, randomized surgical trial to test this hypothesis.
Methods: At least 498 eligible patients from five participating centers will be enrolled and randomized into either
the Pringle group or the non-Pringle group in a ratio of 1:1 using a permuted-blocks randomization protocol. After
the completion of surgical intervention, patients will be included in a 3-year follow-up program.
Discussion: This multicenter surgical trial will examine whether the Pringle maneuver has a negative effect on the
long-term outcome of hepatocellular carcinoma patients. The trial will also provide information about prognostic
differences, safety, advantages and disadvantages between Pringle and non-Pringle surgical procedures. Ultimately,
the results will increase the available information about the effects of ischemia-reperfusion injury on tumor
recurrence, which will be of immense benefit to general surgery.
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Hepatocellular carcinoma (HCC) is one of the most
common cancers worldwide, and has been ranked the
second leading cancer killer in China since the 1990s
[1]. Chronic hepatitis B virus (HBV) infection is the
most common etiology in China [2].
Curative resection remains the best choice of HCC
therapeutic strategies to date, but local tumor recurrence
and remote metastasis unfortunately occur in many
patients who have undergone surgery. Although there
have been great advances in the diagnosis and treatment
of HCC, the long-term prognosis is still unsatisfactory
due to a high incidence of tumor recurrence, ranging
from 50% to 60% [3-6]. The reason for this high recur-
rence rate is not entirely clear. Locoregional tumor re-
currence with concomitant hepatic decompensation is
the main cause of death. It is suggested that further
strategies may be needed for the prevention and treat-
ment of early and late recurrence [7].
The Pringle maneuver is a classical surgical technique
widely used during hepatectomy since its advent in 1908
[8]. During hepatic resection, severe bleeding represents
a major life-threatening risk [9,10]. The Pringle maneu-
ver (continuous or intermittent clamping of the hepatic
artery and portal vein) is routinely used to reduce intrao-
perative bleeding [11,12]. It seems inevitable that man-
euver causes ischemia-reperfusion (I/R) injury, resulting
in complex metabolic [13,14], immunological [15], and
microvascular [16-18] changes, which together might
contribute to hepatocellular damage and dysfunction
[13,19]. Over the past century, the effects of the Pringle
maneuver have been widely discussed [8,20-32]. From
the reported data, we know that the technique can sig-
nificantly reduce blood loss during hepatectomy, mean-
while damaging the liver remnant through the I/R
injury. Interestingly, the effects of the Pringle maneuver
on the prognosis of oncology patients and on the behav-
ior of tumor cells have not been specifically discussed. It
remains unknown whether tumor recurrence and metas-
tasis can be influenced by this surgical stress.
However, this possibility has been raised by the results
of recent animal studies [33,34]. It has been shown that
surgical stress, such as I/R injury, might cause delayed
damage to the residual liver (“soil”), and may also affect
the behavior of the tumor cells (“seeds”) by activating
cell invasion and migration signal pathways, thus accel-
erating tumor recurrence. I/R injury tends to disrupt
normal liver tissues and create an environment that may
promote tumor recurrence. Hepatic resection will also
induce tumor cells to become more aggressive by pro-
moting the production of cytokines by nonparenchymal
liver cells [35]. From the results of these studies, it can
easily be concluded that I/R injury to the liver remnant
may be a significant factor promoting tumor recurrenceand metastasis in experimental animal models. Ani-
mal models may introduce potentially important con-
cepts related to the mechanisms involved in tumor
recurrence associated with surgical stress, specifically
hepatic I/R injury. Furthermore, the promotion of
liver metastasis by hepatic I/R injury during liver re-
section has been reported in colon cancer patients
[36,37], and minimization of I/R injury can attenuate
metastasis of colorectal cancer to the liver [38-40].
Liver transplant recipients with HCC who receive
living-donor grafts experience a higher recurrence
rate [41,42] due to the more severe acute-phase injury
to the liver graft.
For primary liver cancer patient undergoing hepatect-
omy, the effects of I/R injury on tumor recurrence need
to be determined. Because use of the Pringle maneuver
during hepatic resection will lead to I/R injury to the
liver remnant, we can rationally deduce that it may harm
liver function, make the tumor cells more aggressive,
and increase the likelihood of recurrence. If this is found
to be true in humans, routine use of the Pringle maneu-
ver should be re-evaluated. It is unfortunate that there
are currently no reported data or randomized controlled
studies examining this issue.Our hypothesis
We hypothesize that the high incidence of tumor recur-
rence and the poor long-term prognosis of patients with
HCC might be partly due to the I/R injury resulting
from use of the Pringle maneuver during hepatectomy.
If possible, this procedure should be avoided or revised
when performing a hepatectomy on cancer patients [43].
In a clinical setting, many factors such as blood loss,
blood transfusion, liver function, and HBV load affect
the prognosis of cancer patients. These factors may each
have different, and sometimes even opposing, effects on
laboratory test results. However, evaluation of the effects
of the Pringle maneuver remains an important and ur-
gent issue in liver surgery, which may lead to a signifi-
cant change to our current knowledge. We therefore
designed a multicenter, prospective, randomized trial to
test our hypothesis.Methods
Aims of the study
This trial aims to assess the long-term effects of the
Pringle maneuver on the rate of tumor recurrence after
curative resection of HCC. The effects on disease-free
survival, overall survival, operative morbidity and mor-
tality, duration of operation, blood loss, transfusion
requirements, hospital stay, intensive care unit stay, and
blood test results with prognostic relevance, will be
examined. The trial will test whether hepatic resection
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and improves disease-free survival rate.
Trial population
Our study group includes researchers in five leading
hospitals in China (Southwest Hospital, Chinese PLA
General Hospital, Zhongshan Hospital, Nanjing Drum
Tower Hospital, and the First Affiliated Hospital of
SunYet-Sen University) located in the southwestern,
northern, eastern, middle, and southern parts of China,
respectively. All eligible patients from these five partici-
pating hospitals with a clinical diagnosis of HCC with
infection will be enrolled. The study will include
patients’ aged 18 years or older undergoing potentially
curative (R0) resection, if preoperative imaging indicates
that R0 resection can be undertaken both with and with-
out the Pringle maneuver. Patients with extrahepatic dis-
ease, severe liver cirrhosis, or tumor-positive lymph
nodes in the abdomen or hepatoduodenal ligament will
be excluded. We anticipate that 50 eligible cases per
month will be enrolled in the trial. A detailed list of all
eligibility criteria follows.
Eligibility criteria
1. Aged from 18 to 65 years, no gender restriction.
2. Clinical diagnosis of resectable HCC.
3. Liver function tests showing Child-Pugh grade A
and clearance of indocyanine green at 15 minutes
(ICG-R15) less than 15%.
4. Tumor nodes in the liver which can be radically
excised.
5. No preoperative anti-cancer therapy.
6. Written informed consent from the patient or legal
guardian prior to enrollment in the study.Figure 1 Detailed flow chart of the clinical trial. Eligible patients from f
experimental group and a control group by permuted-blocks randomizatio
operation.Exclusion criteria
1. Pregnancy.
2. Extrahepatic tumor or lymph node metastasis.
3. 3.Tumor invasion or thrombosis in the portal vein,
hepatic vein, or inferior vena cava.
4. Surgical marginal positive.
Study design
This study is funded by the National Major Science and
Technology Project of China on the prevention and
treatment of infectious diseases, for human immunodefi-
ciency virus and HBV [2008ZX10002-026]. This clinical
trial is a registered [NCT00725335], prospective, intrao-
peratively randomized multicenter trial of patients
undergoing curative resection for HCC. The patients will
be stratified by center and allocated to groups by a
permuted-blocks randomization protocol. The primary
objective of this study is to compare the disease free-
survival rates at 1, 2, and 3 years postoperatively be-
tween the two groups. We hypothesize that the long-
term prognosis of patients who have undergone curative
resection will be worse in the control group (Pringle
maneuver) than in the experimental group (non-Pringle
maneuver).
The detailed study design is shown in Figure 1.Surgical interventions
All surgical interventions in this trial are described in
the study protocol.
Incision lines and decision-making
Specific teams of surgeons have been designated in each
center participating in this trial, and have completed theive centers will be enrolled, and randomly divided into an
n. Each patient will be followed up for 3 years after their primary
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following the protocol. The abdominal incision can be
decided according to the surgeon’s preference. A
complete exploration of the abdomen and an intraopera-
tive ultrasound evaluation of the whole liver will be per-
formed to decide whether curative resection is feasible.
If necessary, frozen section biopsies will be taken to
evaluate suspicious lesions or lymph nodes. If both inter-
vention procedures seem possible to the surgeon,
randomization will be performed at this time point.
Experimental group (group a, non-Pringle group)
The liver will be mobilized from the retroperitoneum
and the peripheral ligament. Anatomical liver resection
is preferable. If anatomical resection is not possible, a
surgical margin of more than 2 cm should be achieved,
except if the location of tumor nodes makes this impos-
sible (e.g., close to the inferior vena cava or portal vein).
The resection method and surgical margin will be
recorded for analysis. The liver parenchyma can be
resected according to the surgeon’s preference and local
standards (CUSA, Tissue-link.). The Pringle maneuver
will not be used, and hepatic inflow and outflow will be
maintained. For safety, the surgeon may use the Pringle
maneuver if major bleeding occurs.
Control group (group B, Pringle maneuver group)
After mobilization, the Pringle maneuver will be per-
formed. The same approach will be used for hepatic par-
enchymal transection as in the experimental group. If
necessary, the outflow of the hepatic vein can be con-
trolled, and this factor will be analyzed. For safety, the
surgeon may change the surgical technique at any time
during the operation.
Pringle maneuver
The portal triad clamping is set to 15 min hepatic inflow
occlusion followed by 5 min of reperfusion, repeated as
needed. The last occlusion should be 15 min even if the
transection has been completed. The total ischemia and
reperfusion times and the number of occlusion cycles
will be recorded for analysis. Any deviation in the stand-
ard operating procedures will be regarded as a protocol
violation.
Surgical team
The surgical teams consist of senior surgeons who all
have standard qualifications and have independently per-
formed standard anatomical hepatectomy in more than
100 patients. The results of randomization will be made
known to the operating surgeon only after the disease
has been deemed suitable for curative resection. All sur-
gical procedures and anesthesia will be performed by the
specifically trained teams of experienced hepatobiliarysurgeons and anesthesiologists, ensuring standardized
execution of the study protocol. Patients will be ran-
domly assigned to eligible surgeons to minimize the
effects of variations between surgeons on operative
outcomes.
Preoperative examination
Preoperative examination of patients will include blood
biochemistry, alpha-fetoprotein assay, chest x-ray, percu-
taneous ultrasonography, computed tomography (CT)
scan, and hepatic angiography in selected patients. Liver
function will be assessed by Child-Pugh grading and the
indocyanine green clearance test.
Acquisition of samples
Blood samples: Two blood samples will be obtained
from each patient after induction of general anesthesia
through a central venous catheter, which is routinely
placed just before surgery. EDTA (not heparin) will be
used as an anticoagulant for blood samples. Follow-up
blood samples will be collected every 6 months
postoperatively.
Tissue samples: Paracarcinomatous tissue and cancer
tissue will be harvested from the resected liver specimen
at the time of resection. Paracarcinomatous tissue
should be harvested 1 cm from the tumor margin. All
tumors will be pathologically confirmed to be HCC.
Each tissue sample will be divided into two parts, one
of which will be placed in liquid nitrogen and the other
in 10% formalin. Serial 4-μm sections from each speci-
men will be stained with hematoxylin and eosin to deter-
mine clinicopathological features such as venous
invasion, capsule formation, Edmondson’s grade, and cir-
rhotic nodules.
Sample size calculation and data analysis plan
The sample size of this trial was calculated using data
from our previous experience and from the published
literature. There are currently no data from randomized
controlled trials showing the recurrence rate of HCC
after hepatectomy without the Pringle maneuver. Most
studies used the Pringle maneuver. This trial plans to
have equal numbers of control and experimental sub-
jects, and a 36-month follow-up period. The median sur-
vival time after the treatment that the control group will
receive has been reported to be 26 months [24,44-50].
We anticipate a10-month difference in the median
recurrence-free survival time between the experimental
and control groups. If median survival times in the con-
trol and experimental groups are 26 months and
36 months, respectively, we will need to include 249 ex-
perimental subjects and 249 control subjects to be able
to reject the null hypothesis that the experimental and
control survival curves are equal with a probability
Xiaobin et al. BMC Cancer 2012, 12:340 Page 5 of 8
http://www.biomedcentral.com/1471-2407/12/340(power) of 0.800. The Type I error probability associated
with this test of the null hypothesis is 0.05.
Data for primary and secondary outcome measures
will be analyzed using the SPSS statistical software pack-
age (SPSS UK Ltd., Woking, U.K.). Analysis will include
standard descriptive statistics, Student’s t tests, correl-
ation and regression, and two-way (group x time)
repeated measures ANOVA to examine differences be-
tween the groups over time. Survival analysis will be per-
formed. Statistical significance will be set at p < 0.05and
all tests will be two-tailed. Subgroup stratified analysis
will be performed according to tumor size, tumor encap-
sulation, Edmondson’s grade, HBV load, ischemic time,
blood loss, and transfusion. The intention-to-treat ana-
lysis will be used for the patients whose portal triad
clamping was changed due to safety reasons.
Randomization, stratification, and blinding
This is a randomized multicenter study. After giving
informed consent and being enrolled in the study,
patients will be randomized into different groups in
the operating room after surgical exploration. The
permuted-blocks randomization protocol will com-
prise five separate randomization lists, one for each
participating hospital, and will be centrally managed by
the Clinical Trial Center of the lead hospital, the Third
Military Medical University. When an eligible case is
enrolled, the Clinical Trial Center will be called and a
randomization number will be assigned according to
the designated list. Because there are two groups in
this trial, the block sizes will be 4, 6, and 8 and will be
randomly assigned. Patients will be stratified by site
and randomized in a ratio of 1:1 into the two groups.
Patients and outcome assessors will be blinded to
achieve a minimum bias.Endpoints
The primary trial endpoint will be tumor recurrence
diagnosed by enhanced CT scan or serum alpha-
fetoprotein level. Secondary objectives are to examine
overall survival, blood loss, duration of operation, re-
quirement for blood transfusion, length of hospital stay,
and morbidity rate. The formal end of the study will be
at the end of the 3-year follow-up period of the last pa-
tient to be enrolled. All these parameters will be
recorded prospectively as part of the study protocol.
Final evaluation of the primary and secondary endpoints
of the study will be performed 1 year after enrollment of
the last patient.
Clinical evaluation
The clinical evaluation of patients will consist of three
stages: preoperative, intraoperative, and postoperative.During the preoperative stage, the surgeon will evaluate
whether curative resection of the tumor can be per-
formed with and without the Pringle maneuver. For
safety reasons, the operating surgeon can change the
portal triad clamping status at any time during the oper-
ation. If the portal triad clamping is changed, the patient
will still be included in the intention-to-treat analysis. If
a pathological diagnosis of non-primary HCC is made
postoperatively by two different professionals who were
blinded to the treatment, the patient will be excluded.
Safety aspects and adverse advents
Both arms of this trial follow well-established proce-
dures, which are widely used in many surgical centers
allover the world. No specific side effects are expected
other than the known complications of hepatectomy.
The operating surgeon can change the portal triad
clamping protocol at any time during the operation if
necessary to ensure safety. All adverse events during the
hospital stay and follow-up will be recorded for correl-
ation analysis.
Ethics and informed consent
The final version of the study protocol was approved by
the ethics committee of Southwest Hospital, Third Mili-
tary Medical University. This protocol follows all
requirements of the recent German version of the Dec-
laration of Helsinki (Somerset West Version, 1996) and
is in accordance with the principles of Good Clinical
Practice guidelines. The trial has been initiated and will
be carried out following all local legal and regulatory
requirements. The medical secrecy act will also be fol-
lowed. Prior to enrollment in the study, written
informed consent will be obtained from each patient in
oral and written form. Any measures specifically
required only for the clinical trial will not be undertaken
until valid consent has been obtained. Extensive infor-
mation about the intent of the study, the interventions
in each group, the potential associated risks, and poten-
tial alternative therapies will be fully discussed with each
patient. Patients will be also informed that participation
is voluntary and can be withdrawn at any time without
prejudicing their subsequent care. Patients will be
informed of the strict confidentiality of their personal
data collected for this trial, and that their medical
records may be reviewed for trial purposes by authorized
individuals.
Follow-up
Patients who have completed the interventions will be
included in the standard follow-up program. Follow-
up visits will be at 1, 3, 6, 9, and 12 months and then
every 6 months until 3 years after their operation.
Each visit will include physical examination, tumor
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ultrasound examination. In addition, enhanced CT
scans of thorax and abdomen will be performed at 3,
6, 12, 18, 24, 32, and36 months postoperatively. Add-
itional investigations including 18 F-fluorodexyglucose
positron emission tomography scan, magnetic reson-
ance imaging, or digital subtraction angiography will
be scheduled as required to investigate possible tumor
recurrence. At each visit, a follow-up evaluation form
will be completed. If tumor recurs, the patient will be
hospitalized and treated according to the clinical
situation.
Data management and monitoring
The Institute of Hepatobiliary Surgery of Southwest
Hospital is responsible for the coordination of this trial.
The clinical and laboratory data of all patients will be
centrally collected and entered in a password-protected
database at the Clinical Trial Center of Southwest Hos-
pital, Third Military Medical University. All samples and
clinical data will be tracked using a unique research
tracking number. The link between research tracking
numbers and patient identifiers will be kept in a limited-
access database on a computer. Trial data quality reports
will be generated routinely to evaluate missing data and
inconsistencies. Accrual rates and follow-up will be
monitored periodically throughout the study period. If a
potential problem is identified, it will be brought to the
attention of the investigator for discussion and treat-
ment. All operation records will be reviewed to ensure
that the study protocol was followed.
Monitoring of data and patient safety will be per-
formed according to good clinical practice GCP guide-
lines by an independent Data and Safety Monitoring
Board (DSMB) established by the Chinese PLA General
Hospital. The DSMB will meet approximately twice a
year to monitor safety and to advise the centers about
study progress. In addition, the Clinical Trial Center will
provide data to the DSMB Chair at regular intervals, and
at his or her request, to ensure early identification of any
major adverse outcomes of treatment. The DSMB will
monitor adverse effects and respond to variations in the
data, and is responsible for recommending whether the
study should continue, whether the protocol should be
modified, or whether there should be early termination.
Duration of the trial, and current trial status
The trial is planned to last a total of 5 years, consisting of:
protocol development (6 months), training (3 months),
main recruitment (9 months), follow-up (36 months), and
analysis (6 months). All the team members have com-
pleted their training. The expected end date of this trial
will be July, 2013.Discussion
Even though short-term outcomes of the Pringle maneu-
ver have been investigated, its effects on tumor recur-
rence and metastasis have not been discussed. This trial
will focus on the effects of the I/R injury caused by the
Pringle maneuver on the long-term prognosis of primary
HCC patients with HBV infection.
Previous experimental studies have demonstrated that
tumor recurrence could be increased by I/R injury to the
liver remnant, and that the tumor cell might become
more aggressive [33,35]. If this occurs in the clinical set-
ting, use of the Pringle maneuver must be re-evaluated,
because it has been widely performed in the past to
avoid massive blood loss during hepatic resection. The
Pringle maneuver may cause additional I/R injury be-
sides that caused by the hepatic resection itself, which
will affect tumor cells and the liver remnant.
With advances in surgical techniques and periopera-
tive management, portal triad clamping is not necessary
for every hepatectomy, and it may be important to fur-
ther discuss its use. We hypothesize that the prognosis
of patients with primary HCC might be worsened by use
of the Pringle maneuver during hepatectomy. If this is
true, this routine surgical technique should be revised or
even avoided during hepatectomy, especially in HCC
patients. We all know that it can take time for theories
based on animal experiments to have an effect on clin-
ical practice. In some cases, the final outcome may be
affected by multiple clinical factors. For this trial,
reported data indicate that these factors mainly include
the hepatitis virus DNA load, surgical margins, micro-
vascular thrombosis, tumor size, number of tumor
nodules, microvascular invasion, tumor capsule forma-
tion, blood loss, and blood transfusion. We take all these
factors into account in our inclusion and exclusion cri-
teria and subgroup analysis. Whatever the results of this
randomized controlled trial, we will gain important in-
formation about the long-term effects of the Pringle
maneuver.
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